Suppr超能文献

On bias and transparency in the development of influential recommendations.

作者信息

Laupacis Andreas

机构信息

Institute for Clinical Evaluative Sciences and the University of Toronto, Toronto, Ont.

出版信息

CMAJ. 2006 Jan 31;174(3):335-6. doi: 10.1503/cmaj.051622.

Abstract
摘要

相似文献

1
On bias and transparency in the development of influential recommendations.
CMAJ. 2006 Jan 31;174(3):335-6. doi: 10.1503/cmaj.051622.
2
Analysis of American College of Cardiology/American Heart Association Guideline Author Self-Disclosure Compared With Open Payments Industry Disclosure.
Circ Cardiovasc Qual Outcomes. 2019 Dec;12(12):e005613. doi: 10.1161/CIRCOUTCOMES.119.005613. Epub 2019 Dec 3.
3
Commercialism and medicine: an overview.
Camb Q Healthc Ethics. 2007 Fall;16(4):377-86; discussion 439-42. doi: 10.1017/s0963180107070478.
4
New rules on conflict of interest: what has to be done in Europe?
Tumori. 2010 Jan-Feb;96(1):180-1. doi: 10.1177/030089161009600133.
5
Transparency is key.
Dtsch Arztebl Int. 2014 Jan 17;111(3):37. doi: 10.3238/arztebl.2014.0037a.
6
Expert evidence: do you have all the facts?
BJU Int. 2000 Aug;86(3):291-3. doi: 10.1046/j.1464-410x.2000.00295.x.
7
ACCF/AHA consensus conference report on professionalism and ethics.
Circulation. 2004 Oct 19;110(16):2506-49. doi: 10.1161/01.CIR.0000147952.60985.b0.
8
Task force 5: Expert testimony and opinions.
J Am Coll Cardiol. 2004 Oct 19;44(8):1747-9. doi: 10.1016/j.jacc.2004.08.042.
10
Ethics and Disclosure.
Foot Ankle Int. 2019 Mar;40(3):364. doi: 10.1177/1071100719826957. Epub 2019 Jan 30.

引用本文的文献

1
Policies on doctors' declaration of interests in medical organisations: a thematic analysis.
J R Soc Med. 2023 Sep;116(9):295-306. doi: 10.1177/01410768231181248. Epub 2023 Jun 8.
2
Financial Conflicts of Interest in Propensity Score-Matched Studies Evaluating Biologics and Biosimilars for Inflammatory Bowel Disease.
J Can Assoc Gastroenterol. 2022 Jun 1;5(5):214-220. doi: 10.1093/jcag/gwac018. eCollection 2022 Oct.
3
Financial Conflicts of Interest in Clinical Practice Guidelines: A Systematic Review.
Mayo Clin Proc Innov Qual Outcomes. 2021 Jan 19;5(2):466-475. doi: 10.1016/j.mayocpiqo.2020.09.016. eCollection 2021 Apr.
5
Transparency in reimbursement decisions: in whose best interest?
Pharmacoeconomics. 2014 Aug;32(8):725-7. doi: 10.1007/s40273-014-0176-4.
6
Guideline standardisation, cost effectiveness, industry needs and conflict of interest.
Mens Sana Monogr. 2007 Jan;5(1):56-78. doi: 10.4103/0973-1229.32150.
7
Conflict of interest in clinical practice guideline development: a systematic review.
PLoS One. 2011;6(10):e25153. doi: 10.1371/journal.pone.0025153. Epub 2011 Oct 19.
8
Moving from opacity to transparency in pharmaceutical policy.
CMAJ. 2008 Feb 12;178(4):428-31. doi: 10.1503/cmaj.070799.
9
Evidence and advocacy: are all things considered?
CMAJ. 2006 Jun 20;174(13):1856. doi: 10.1503/cmaj.060231.

本文引用的文献

1
Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction.
Can J Diabetes. 2013 Apr;37 Suppl 1:S1-3. doi: 10.1016/j.jcjd.2013.01.009. Epub 2013 Mar 26.
2
Conflicts of interest and independent data analysis in industry-funded studies.
JAMA. 2005 Nov 23;294(20):2575; author reply 2576-7. doi: 10.1001/jama.294.20.2575-a.
3
Challenges in systematic reviews that assess treatment harms.
Ann Intern Med. 2005 Jun 21;142(12 Pt 2):1090-9. doi: 10.7326/0003-4819-142-12_part_2-200506211-00009.
4
Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors.
CMAJ. 2005 Jun 21;172(13):1700-2. doi: 10.1503/cmaj.050600. Epub 2005 May 23.
6
Publication bias in clinical research.
Lancet. 1991 Apr 13;337(8746):867-72. doi: 10.1016/0140-6736(91)90201-y.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验